Valneva SE (VALN) Form 6-K — Oct 8, 2026
Valneva announced that the UK MHRA revoked the marketing authorization for IXCHIQ following a benefit-risk reassessment by the Commission on Human Medicines. The decision was based on previously known safety data and no new safety signal was identified. The revocation has limited financial consequences: Valneva launched IXCHIQ in the UK in mid-2025 but stopped distributing it there months ago due to low traveler sales, so it expects no recall expense and only minimal impact on future revenue. The company decided not to appeal given the immaterial impact.
Key figures
- Uk launch
- mid-2025
- Brazil pvs vaccinated
- more than 61,000 people aged 18-59 years
- Doses administered globally
- approximately 187,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.